Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate
Protein formulation development relies on the selection of excipients that inhibit protein–protein interactions preventing aggregation. Empirical strategies involve screening many excipient and buffer combinations by physicochemical characterization using forced degradation or temperature-induced st...
Saved in:
Main Authors: | Tobias M. Prass, Patrick Garidel, Lars V. Schäfer, Michaela Blech |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2427771 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
by: Kristina M.J. Aertker, et al.
Published: (2024-12-01) -
IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria
by: Luis Felipe Ensina, et al.
Published: (2025-01-01) -
Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling
by: Eliott Park, et al.
Published: (2024-12-01) -
Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers
by: Yutong Sima, MD, et al.
Published: (2025-01-01) -
Reduction of monoclonal antibody viscosity using interpretable machine learning
by: Emily K. Makowski, et al.
Published: (2024-12-01)